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Funding  of  diagnostic  and  therapeutic  methods  in Germany’s  statutory  health  insurance
(SHI)  follows  a dichotomy:  in outpatient  care,  only  methods  with  proven  beneﬁt  are  reim-
bursed while  in  inpatient  care,  all methods  may  be  provided  unless  they  are  excluded
due  to  proven  harm  or lack  of  beneﬁt.  In January  2012,  a  new  section  137e  was  added  to
the  Social  Code  Book  V (SGB  V),  allowing  for the inclusion  of innovative  and  potentially
beneﬁcial  diagnostic  or therapeutic  methods  in the  SHI  beneﬁt  basket,  while  additional
evidence  regarding  their  effectiveness  and  safety  must  be gathered.  In  2013,  the  Federal
Joint  Committee  (G-BA)  has  speciﬁed  the  details  of  this  new  approach,  which  can  be  con-
sidered  a variety  of  “Coverage  with  Evidence  Development”  (CED).  Our comparison  with
CED schemes  in selected  countries  reveals  a dependence  of the CED  implementation  on
the encompassing  healthcare  system.  However,  we  identify  a clear  legislative  foundation,
a  deﬁnitive  decision-making  body,  the  possibility  to  obtain  public  funding,  and  the  pref-
erence  for  high  quality  study  designs  as  constituting  factors  of an  emerging  international
standard  for  CED.  In addition,  it is necessary  to ensure  the  suitability  of  circumstances
and  technologies  for the  successful  application  of  CED  in a clear  and  transparent  way.
©  2014  Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC BY-NC-ND  license. IntroductionThe principles of evidence-based medicine (EBM) have
ecome standard for all levels of healthcare decision-
aking [1]. However the EBM approach has shortcomings
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in the adoption of promising technologies that are poten-
tially beneﬁcial for patients, highly cost-effective or even
cost-saving, but for which the quality of evidence is insuf-
ﬁcient to justify full coverage [2]. One common approach
that has been used in resolving this dilemma is health tech-
nology assessment (HTA). HTA has been widely adopted to
support decision-making regarding the introduction and
adequate use of new technologies. Nevertheless, the major-
ity of HTA activities have been limited to pharmaceuticals.
Other interventions – also called ‘methods’ – such as new
medical devices or procedures (surgical and non-surgical)
have less often, or never, been assessed by HTA before
implementation [3]. Dealing with the shortcomings of
EBM and HTA as well as the increasing pressures on health
 BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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care budgets of costly innovative treatment options, policy
makers and key stakeholders have begun to invest in new
approaches to initiate and use clinical research [2,4].
One option within this context is the coverage with
evidence development (CED) approach. CED represents a
speciﬁc policy tool, providing provisional access to novel
medical interventions while the evidence needed to assess
the value of an intervention and consequently to make cov-
erage unconditional is generated [5]. Thereby it addresses
the needs of different stakeholders such as decision mak-
ers, manufacturers, patients, and health service providers
[3,6]. For example, CED offers an option for government
bodies to make a technology available in a controlled man-
ner while in addition allowing them to predetermine which
evidence will be needed to ensure further use and cover-
age of the technology. From the manufacturers’ perspective
(e.g. medical device companies), CED gives the opportunity
to introduce a new and promising technology which oth-
erwise might be rejected. Last but not least, CED might be
relevant for healthcare providers and the patients, because
it provides earlier accessibility to promising technologies
and consequently a broader range of available treatment
options [3]. CED – in some way or form – has already been
implemented in many countries throughout the world (e.g.
Australia, United Kingdom (UK), France, The Netherlands
or Canada), usually as part of an established policy frame-
work [7]. In consequence, it is known under various terms
such as ‘interim funding’ [8], ‘only in research (OIR)’ [9],
‘still in clinical research’ [10], and ‘conditionally funded
ﬁeld evaluation (CFFE)’ [11]. However, the term CED has
been coined by the Centers for Medicare & Medicaid Ser-
vices (CMS) in the United States (US), which published
guidelines regarding the relevance and use of CED in 2005.
Further revisions followed in 2006 and most recently in
2012/2013 [12]. Increasingly, attempts are being made to
further develop or expand such CED mechanisms and tai-
lor them to countries’ speciﬁc health care systems [5,6].
One recent example is the new regulation in Germany. In
January 2012, a new section 137e has been added to the
German Social Code Book V (SGB V). It can also be seen as a
further scheme within the scope of CED approaches. While
plenty of literature on the varying established CED schemes
exists, little or no description and analysis of this new legis-
lation in Germany has been conducted so far [5,7,9,11,13].
Additionally, the introduction of yet another CED scheme
prompts the question whether a standard in CED is
emerging.
Therefore our primary goal in this study is to give a
more detailed understanding of the new German regula-
tions regarding section 137e SGB V as a further variation of
the CED approach. As the new regulation does not concern
pharmaceuticals, this manuscript focuses only on diag-
nostic and therapeutic methods. It gives insight into the
motives for implementing this new regulation, the relevant
speciﬁcs, the general evaluation procedure, followed by a
description of the consequences for the in- and outpatient
care setting, and an outlook regarding the impact of the
new regulation. We  will further compare the new German
regulation to other representative examples of CED direc-
tives in an outside Europe in order to answer the question
whether an international standard is emerging. 117 (2014) 135–145
2. The regulation of diagnostic and therapeutic
methods in the in- and outpatient care setting in
place prior to the reform
In Germany’s statutory health insurance (SHI) system,
newly licensed pharmaceuticals and diagnostic or thera-
peutic methods are regulated in different ways. However,
both are regulated by the same decision-making body, the
Federal Joint Committee (G-BA). The G-BA is the high-
est decision-making body of the joint self-government of
physicians, dentists, hospitals, patients and health insur-
ance funds in Germany. It issues directives for the beneﬁt
basket of the statutory health insurance funds for more
than 70 million insured individuals and thus speciﬁes
which services in medical care are reimbursed by the SHI.
In addition, the G-BA speciﬁes measures for quality assur-
ance in inpatient and outpatient areas of the health care
system [14]. As mentioned in the beginning, this article will
focus only on diagnostic and therapeutic methods. An up-
to-date analysis of recent changes regarding the regulation
of pharmaceuticals in Germany can be found in Henschke
et al. [15].
According to the Federal Social Court (e.g. case no.
B 1 KR 10/09 R) a diagnostic or therapeutic method is
generally deﬁned as a medical procedure embedded in a
treatment plan under a physician’s care, based on a spe-
ciﬁc theoretical and scientiﬁc concept. It involves several
steps usually involving medical devices differentiating it
from other (one-step) procedures and thus justifying its
systematic application in the examination and treatment
of speciﬁc diseases [16]. This understanding of a method
comprises a broad spectrum of new diagnostic and ther-
apeutic methods and entails a broader concept than the
application of medical devices alone, such as medical aids.
However, not every new non-pharmaceutical treatment
can be seen as a method [17]. For example, if a patient
takes daily blood pressure measurements to monitor her
blood pressure levels herself, this does not yet constitute
a method. If, however, the blood pressure measurements
are part of a Disease Management Programme (DMP) and
are being transmitted to the patient’s doctor in order
to facilitate treatment adjustments, they do constitute a
method.
So far, diagnostic and therapeutic methods in the in- and
outpatient sector only come under consideration by the
G-BA when a stakeholder organisation – this includes the
impartial members of the G-BA, the regional associations
of SHI physicians, the federal association of SHI physicians
(KBV), the federal association of statutory health insurance
funds (GKV-SV), or the patient representatives in the G-BA
– applies for a beneﬁt assessment. This is usually the case
when there is uncertainty regarding the patients’ beneﬁt of
a method. There are two different existing routes to inclu-
sion of diagnostic and therapeutic methods into the beneﬁt
basket in Germany:
(1) Methods intended for use in the outpatient care set-
ting are regulated by section 135 of the SGB V. The
regulation includes a so-called prohibition rule with the
reservation of permission.  Under this rule, new diag-
nostic and therapeutic methods are only added to the
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beneﬁt basket if the G-BA comes to a positive decision
regarding these methods [18]. A positive decision will
only be achieved if the beneﬁt of a new method has
been proven by sufﬁcient evidence based on available
studies. In addition, based on section 12 (subsection 1)
SGB V, the method has to be medically necessary
and economically efﬁcient [18]. Positively evaluated
methods are added to the Physicians’ or Dentists’ Uni-
form Value Scale (Einheitlicher Bewertungsmaßstab or
Einheitlicher Bewertungsmaßstab für zahnärztliche Leis-
tungen), which list reimbursable services and thus also
serve as beneﬁt catalogues for the respective sectors
[19].
2) In contrast, in the inpatient care setting, section 137c
SGB V deﬁnes the principle of permission unless explic-
itly banned. This means that all methods – including
new ones – can be used without any acknowledgement
of beneﬁt as long as the G-BA does not explic-
itly ban a method based on the available evidence.
Most established methods are included in the cost
calculation of the German Diagnosis-Related Group
(DRG) system and thus in the DRG payments or
supplementary payments by the sickness funds [20].
New diagnostic and therapeutic methods may  qual-
ify for extra-budgetary “NUB” (new examination and
treatment methods) payments if (1) they are more
expensive than the one included in the calculation of an
existing DRG and if (2) a funding agreement has been
reached between sickness funds and hospitals on a local
level [21].
As the description of the two routes regarding the
mplementation of new diagnostic and therapeutic meth-
ds into the beneﬁt basket illustrates, the G-BA has the
egislative tools to exclude methods because of proven
arm or a lack of evidence for patient beneﬁt, but no valid
ptions to request the generation of evidence [22].
. The coverage with evidence development
eform—New section 137e SGB V
The G-BA evaluates the beneﬁts of treatment meth-
ds by applying the criteria of EBM [1]. After a systematic
earch for the best available evidence on the topic of inter-
st, results are evaluated with respect to their validity,
lausibility and applicability. Under the principles of EBM,
ethods would not be excluded due to a lack of posi-
ive demonstration of an added beneﬁt, as it would be
nadequate to infer a lack of beneﬁt from missing evi-
ence [22,23]. The G-BA therefore needs a mechanism for
nducing the generation of scientiﬁc evidence for decision-
aking in the EBM framework. Such a mechanism is
rovided by section 137e SGB V.
.1. Motives for implementation
Criticism had been raised particularly regarding the reg-
lations in the inpatient care setting. As new diagnostic
nd therapeutic methods do not have to undergo a struc-
ured assessment under section 137c before being provided
n hospitals, the patient-beneﬁt (or possible risk) often 117 (2014) 135–145 137
remains uncertain for the patient, mainly due to the lack
of evidence from high quality studies.
Experiences with lengthy and controversial decisions
regarding the exclusion of methods by the G-BA have
shown that the conditions for the generation of knowledge
that are needed for decision making must be improved [24].
One example is positron emission tomography (PET) for
different indications, which has been under consideration
since 1998. The G-BA could only form a decision on ﬁve
indications and excluded PET for three (partly in two of the
three cases) of them. For two  other indications (colorec-
tal and esophageal cancer) the decision-making process
was suspended due to remaining uncertainties about the
evidence and coinciding signs for being a valid treatment
alternative. About ten more indications are currently under
consideration.
In addition, no information about the number of meth-
ods implemented in the clinical care setting without proven
evidence is available [22]. Only since the year 2000, some
of the most controversial diagnostic and therapeutic meth-
ods have been brought to consideration by the G-BA and a
number of them have been excluded due to lack of evidence
or because of an unfavourable beneﬁt–risk assessment.
Table 1 aims at giving an overview of currently excluded
hospital treatment methods. At the moment (only) 15
methods in the inpatient care setting are excluded by the
G-BA based on the lack of evidence for patient beneﬁt [25].
3.2. Speciﬁcs of the new stipulation
With the introduction of the new section 137e SGB V
through the SHI Care Structures Act (GKV-VStG) in January
2012, a new legal tool has been created to prospectively test
innovative diagnostic and therapeutic methods that have
the potential to be viable alternative to the current standard
under structured conditions. A diagnostic and therapeutic
method is deﬁned as new if:
- it is not listed in relevant documents like the Physicians’
or Dentists’ Uniform Value Scale or
- it is listed in the Physicians’ or Dentists’ Uniform Value
Scale, but shows substantial changes regarding its indi-
cation or how it is delivered, and
- the method under evaluation falls within the scope of
statutory health insurance in Germany, as stated in the
second chapter, section 2 of the rules of procedure of the
G-BA (Verfahrensordnung) [26].
The new stipulation has a sound legal basis (SGB V),
which is legitimised by the German Parliament, and com-
plements the regulations under sections 135 and 137c. All
details regarding the trial procedures in accordance with
section 137e SGB V are deﬁned in the G-BA’s rule of proce-
dure [26].
A key element when assessing a new method under
section 137e SGB V is that it needs to show potential
for additional patient-relevant beneﬁt in comparison to a
current standard or benchmark method. The G-BA dele-
gates the evaluation of new candidate methods regarding
their potential for improvement to the Institute for Qual-
ity and Efﬁciency in Health Care (IQWiG). In general,
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Table 1
Excluded inpatient treatment methods (in chronological order of initial decision).
Excluded diagnostic and therapeutic methods—inpatient care setting (section 137c) Year of decision
Autologous chondrocyte implantation (ACI); in 4 indications 2003: 2 indications; 2009: 1 indication; 2010: 1
indication
Hyperbaric oxygen therapy (HBOT); in 8 indications 2003: 2 indications; 2004: 3 indications; 2008: 1
indication; 2009: 2 indications
Proton beam therapy; in 10 indications 2003: 3 indications; 2007: 1 indication; 2009: 3
indications; 2010: 2 indications; 2011: 1 indication
Positron emission tomography (PET; PET/CT); in 3 indications 2008: 2 indications; 2011: 1 indication
Both  hybrid-laser-treatments potassium-titanyl-phosphate/neodymium yttrium
aluminium garnet (KTP/Nd:YAG) and contact-laser-ablation/visual laser-ablation
(CLAP/VLAP) for the treatment of benign prostatic syndrome (BPS)
2010
Interstitial laser coagulation (ILK) for the treatment of benign prostatic syndrome (BPS) 2010
Holmium-laser ablation (HoLAP) for the treatment of benign prostatic syndrome (BPS) 2010
Holmium-laser bladder neck incision (HoBNI) for the treatment of benign prostatic
syndrome (BPS)
2010
Transurethral radiofrequency needle ablation (TUNA) for the treatment of benign
prostatic syndrome (BPS)
2010
High intensity focused ultrasound (HIFU) for the treatment of benign prostatic
syndrome (BPS)
2010
Water induced thermotherapy (WIT) for the treatment of benign prostatic syndrome
(BPS)
2010
Transurethral ethanol ablation (TEAP) for the treatment of benign prostatic syndrome
(BPS)
2010
Thulium-laser ablation (TmLAP) for the treatment of benign prostatic syndrome (BPS) 2011
Autologous stem cell transplantation for the treatment of acute lymphoblastic
leukemia (ALL) in adults
2011
Exclusive use of antibody-coated stents for the treatment of coronary vessel stenosis 2013Source: [25] (in German).
demonstrating that a new diagnostic and therapeutic
method is not being harmful or ineffective is not enough to
fulﬁl the underlying concept of potential. To show poten-
tial, the method rather needs to demonstrate potential
based on the mechanism of action and the evidence avail-
able so far. In particular, this means it should be more
effective, less complicated, less invasive, or less harmful or
able to replace less efﬁcacious methods in speciﬁc groups
of patients. The method may  be an optimisation of an exist-
ing treatment, or otherwise lead to an improvement in the
medical treatment. [27]. It is also crucial in this context
that the scientiﬁc documents submitted by the applicant
are sufﬁcient to serve as a basis for clinical study planning
in order to assess a new method’s beneﬁt with sufﬁcient
certainty. However, the key items of the trial phase, such
as indication, study population, intervention, study design,
appropriate comparator, outcomes, study duration, prac-
tical/staff, and other quality requirements necessary to
specify the research question, are determined by the G-BA
in accordance with chapter two (section 22), of the rules of
procedure. Applicants have the opportunity to issue theirviews in a comments procedure before a clinical trial is
commissioned [26].
The speciﬁcs regarding costs of the trial phase and their
reimbursement are deﬁned in the G-BA’s schedule of costs
[28]. Generally, costs during the assessment phase for the
service provision itself will be covered by the sickness funds
[18,28]. Manufacturers only have to pay for overhead costs
of the clinical trial if a medical device is essential for the new
method. These overhead costs include costs for the prepa-
ration of a study protocol, the scientiﬁc monitoring and the
evaluation of the study results, which are all performed by
an independent scientiﬁc institute [18,26].
3.3. Procedures and decision-making under the new
stipulation
Until now, only the stakeholder organisations and the
impartial members, as given above, have been allowed
to submit requests calling for an assessment of new or
already established and reimbursed diagnostic or thera-
peutic methods to the G-BA (see section 2). According to
B. Olberg et al. / Health Policy 117 (2014) 135–145 139
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he revised rules of procedure, for the ﬁrst time, man-
facturers of medical devices, and other companies that
ave an economic interest in their provision, are granted
o speciﬁcally apply for the testing of new diagnostic and
herapeutic methods under the new section 137e SGB V
18]. Applications may  also be submitted for methods not
equiring a medical device (e.g. manual therapy or psy-
hotherapy). Fig. 1 gives a simpliﬁed representation of the
hree coexisting decision-making processes regarding new
nd already established diagnostic and therapeutic treat-
ent methods in the in- and outpatient care setting [29].
On the basis of such a request for assessment by the
anufacturer, the G-BA commissions the IQWiG to evalu-
te the potential of the new method. In case, the G-BA – on
he basis of the IQWiG’s results – assesses the method as
howing potential and decides to conduct a trial, it devel-
ps and publishes a directive that deﬁnes a trial phase for
he method in question and commissions an independent
cientiﬁc institute to plan and conduct the evaluation [26].
uch a trial phase only exists under the new section 137e
GB V.
Once the trial phase is completed, the G-BA re-evaluates
he trial data and makes a ﬁnal decision whether the
ethod is approved or rejected. There is no predeﬁned
ime frame for this reassessment. Should the trial results
emonstrate an additional patient beneﬁt, the G-BA
pproves the new method as reimbursable in the in- and
utpatient sector. Conversely, if – under the new stipula-
ion – the new method shows no potential or the clinical
ata gathered during the trial phase does not show that
he new method serves as a valid treatment alternative,
he G-BA publishes a directive in which the new method
s added to the ‘exclusion list’ (Annex II of the Guidelinesd outpatient care setting (simpliﬁed overview) [29].
on SHI accredited outpatient methods, as seen in Table 1).
Methods listed in Annex II are not reimbursed by the
sickness funds [18]. In some cases the testing phase may
not come into being even if the method displays potential
(e.g. because a manufacturer refuses to pay for the over-
head costs). However, unless a method was evaluated in
a clinical trial and afterwards added to the ‘exclusion list’,
manufacturers may  apply for reassessment after a waiting
period of one year (see Fig. 1).
3.4. Consequences for the in- and outpatient care setting
Due to the different reimbursement rules in German
ambulatory and inpatient care, the new regulation may
impact these two  sectors differently.
First, it offers a chance for new methods in the outpa-
tient care setting to transform the prohibition rule with the
reservation of permission (according to section 135 SGB V)
into a conditional permission until a ﬁnal decision has been
reached based on the gathered clinical data during the trial
phase [30].
Second, prior to the new regulation, there were three
possible outcomes for methods assessed regarding the
inpatient care setting (see Fig. 1): (i) conﬁrmation of
patient-relevant beneﬁt, (ii) exclusion of the method
because of lack of evidence or evidence for harm and (iii)
suspension of the consideration because of lack of evidence.
While exclusion of the method refers to an immediate
exclusion from any insurance reimbursement, suspension
of the consideration does not. In the latter case, the method
is being reimbursed for a temporary period, while new evi-
dence may  be gathered. In some cases, the G-BA might
have suggested a speciﬁc study design, but there was  no
h Policy140 B. Olberg et al. / Healt
possibility for the G-BA to enforce the generation of evi-
dence. Under the new stipulation – in case of insufﬁcient
evidence – the assessment is suspended as under the pre-
vious legislation but a clinical trial has to be initiated, if the
method shows potential to be beneﬁcial. Exclusion under
section 137e, is only possible if the results of the initiated
trial show lack of beneﬁt or even harm or if the trial does
not come into being [18]. In addition, diagnostic and thera-
peutic methods that are suspended under section 137c due
to uncertainties regarding the evidence but show potential
and trial registries do not indicate one or more relevant
studies to be published soon, now have to come under
consideration through section 137e (see Fig. 1).
3.5. Outlook
The G-BA has amended its rules of procedure in order
to translate the legal mandate into a manageable process.
This amendment has been published in June 2013 in the
Federal Gazette [31]. Currently, only one assessment under
the new regulation has been initiated (PET in the indication
for colorectal cancer). Over the coming years, more deci-
sions on new methods will follow. However, the type and
exact number of methods is not clear yet. It is expected
that applications with regard to the new CED pathway
will mainly concern the outpatient sector, since new meth-
ods require G-BA approval. Nevertheless, applications may
also be ﬁled for conducting studies in the hospital sector,
despite explicit approval by the G-BA being unnecessary.
In addition it is anticipated that companies will seek
advice regarding the formalities of the application process,
methodological requirements for the assessment, suitabil-
ity of a new method for consideration under section 137e
SGB V, and funding speciﬁcs. The G-BA ofﬁce will provide
such advice in co-operation with a dedicated working
group of the G-BA [26].
4. Discussion and international comparison
Having described the details of the new German leg-
islation, we now discuss its possible advantages and
disadvantages. The main improvement of section 137e SGB
V is that it allows for new and potentially beneﬁcial meth-
ods in the inpatient care setting to be scheduled for trial
before exclusion from coverage, if these methods lack evi-
dence regarding their effectiveness and safety. In addition
in the outpatient care setting, physicians and patients may
get access to new and promising treatment options ear-
lier. The approach is innovation-friendly and attractive for
manufacturers mainly in the outpatient sector, since they
are able to conduct studies that are ﬁnancially supported by
the sickness funds (payment for the service provision). In
addition, the legislation is expected to reduce the duration
of the G-BA’s consultation procedures, because it facilitates
the decision by the G-BA’s stakeholders in cases lacking
sufﬁcient evidence. Although the new stipulation is a use-
ful development with respect to the assessment of new
and promising methods, it also suffers from several limi-
tations worth considering: under the legislation, exclusion
of a new method in the absence of evidence is no longer
possible in the inpatient setting, as the G-BAs’ assessment 117 (2014) 135–145
needs to show that the method is either less effective than
the standard treatment or harmful. If a method is proven
to be less effective or even harmful after ﬁnalisation of a
CED trial, it has to be delisted from the beneﬁt catalogue,
although controversies will be likely. This applies to the
inpatient sector, since some of these methods might have
been part of routine care since decades.
Furthermore, when the G-BA initiates a study, the new
method can also be applied in the inpatient setting out-
side the trial, which may  lead to difﬁculties in patient
recruitment. Therefore, it is to be expected that the Ger-
man  CED approach is less attractive for setting up studies
in the inpatient sector. In addition, due to the lack of
proven beneﬁt, the risk for the patient to be exposed to
potentially ineffective or even harmful treatment methods
during the evaluation is not mitigated. From the perspec-
tive of the SHI system, patients are exposed to potentially
ineffective and expensive methods during the evidence
development phase. Furthermore, it will be challenging
to draw a line between sufﬁcient evidence for demon-
stration of the potential and the evidence necessary for
planning a study (e.g. a RCT) [26,27]. Finally, issues that
need to be addressed in the future remain. The G-BA has
no ability to rule out the ‘free-rider phenomenon’, i.e. a
company with an innovative device pays for a clinical
trial and another competing company launches its product
after the (successful) evaluation and thus beneﬁts from the
pioneering company’s investment. The procedure is still
time-consuming. On average it takes 30 months, excluding
the duration of the trial. A priority-setting process has not
been established yet since it is not clear how many appli-
cations will be ﬁled. This could become a matter of critique
in the future, when the number of methods with a poten-
tial for additional patient beneﬁt will exceed the capacity
of the G-BA to manage them.
The new stipulation in Germany adds to the mix  of
already implemented CED schemes in- and outside Europe.
Therefore it is only logical to ask how well the new German
approach fares in comparison to other implementations
of CED internationally. Moreover we are interested in
investigating whether an international standard for CED is
emerging. To achieve this we  provide information about
key political, structural and methodological attributes
of different CED schemes from selected countries in
Table 2.
The respective countries are chosen as representative
examples of different Western health care systems ran-
ging from single-payer schemes to social insurance models.
We  do not intend to give a complete review of existing
international approaches. Our data mainly stem from infor-
mation available in the public domain (e.g. governmental
and related organisations’ webpages). Where necessary we
ﬁll the gaps with data available in the literature or informa-
tion obtained directly from the individuals involved in the
decision process regarding conditional reimbursement of
new diagnostic and therapeutic methods in a given country
(e.g. inside the relevant institution or organisation).The comparison shows that the German implemen-
tation of CED does, indeed, have features in common
with its international counterparts. However, there are
still differences with respect to the schemes’ structures,
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Table 2
Comparative overview of key attributes across CED schemes (as of April 2014; in alphabetical order).
Attributes Australia Canada (Ontario) France Germany The Netherlands UK (England/Wales) USA
Name of the CED
system
Interim funding Conditionally funded
ﬁeld evaluation
Still in clinical
research
Evaluation of new
diagnostic and
therapeutic methods
Conditional entry into the
basic packagea
Only in research Coverage with
evidence
development
(Legal)  basis Health Insurance
Act (1973)
Administration/delivery
of healthcare services
is each
province’s/territory’s
responsibility based on
the Canada Health Actb
Article L.165-1-1 of
the French health
social security code
(‘Forfait innovation’)
Section 137e of the
Social Code Book Five
(SGB V)
As of 1 January 2012 rooted
in the health care law
MTG/DG is advisory;
IPG can limit use of
interventional
surgical/other
procedures if limited
evidence for safety
and/or efﬁcacy is
limited
Section 1862
(a)(1)(A) of the Social
Security Act, called
the “reasonable and
necessary” statute
Funding Mainly public
(department of
Health and Aging)
Public (by MOHLTC) Mainly private
(manufacturers);
HAS is not involved
in the choice of
ﬁnancing modality
Public/private.
Manufacturers pay
overhead costs of
clinical trial; costs of
service provision
during trial phase
will be covered by
the SHI funds
Public (by ZonMw; certain
budget available but not
obligatory) and private
((co)funding by industry or
other parties possible)
Both private
(manufacturer) or
public (NICE or other
UK public funders
such as NIHR and
MRCc)
Researchers must
ﬁnd own  funding;
some studies are
government funded;
most others are
privately supported
(e.g. manufacturer)
Decision-making
body
Department of
Health and Aging
Ministry of Health and
Long-Term Care
Ministry of Health Federal Joint
Committee
Ministry of Health, Welfare
and Sport
NICE Centers for Medicare
& Medicaid Services
Involved third parties
(e.g.
academic/scientiﬁc
institutions,
research groups. . .)
MSAC for evidence
advise, other
partners (e.g.
health
professionals)
OHTAC/MAS/PATH,
THETA, other partners
(e.g. academic health
science centres, disease
speciﬁc agencies)
HAS, CNEDiMTS,
CEPS, DGS (request
and/or assessment of
methodology);
manufacturers (data
collection)
Independent
scientiﬁc institute,
IQWiG assesses
eligibility according
to potential of beneﬁt
Zorginstituut Nederland,
DBC-O, NZa and ZonMw,
other partners (e.g. health
professionals, academic
institutions, manufacturers)
NICE, other partners
(health professionals,
manufacturers)
AHRQ, MEDCAC,
other partners
(institutions, health
professionals)
Subject  of assessment ‘Service’ is used
generically;
encompasses
clinical procedures,
diagnostic tests,
medical services
and health
technologies
Includes medical
devices, procedures
and other non-drug
health technologiesd
Medical devices and
procedures
New diagnostic and
therapeutic methods;
also methods
without a medical
device as essential
for the new method
‘Medical care (incl. specialist
drugse)’ refers to: care
provided by GPs, medical
specialists, ﬁrst line
psychologists and
obstetricians. Since 1 January
also outpatient pharmacy
Devices that have
been subject of NICE
guidance (either CE
marked or adjunct
drugs), in-vitro
diagnostics that may
not have a CE mark,
interventional
procedures, public
health interventions
Surgery, medical
devices that might be
implanted or used
externally, services
that occur in
physician’s
ofﬁce/ambulatory
centre, injectable
drugs
Topic
selection/reasons
for  applying CED
On a case-by-case
basis; if there is
inconclusive
evidence on safety,
effectiveness and
cost- effectiveness
Large potential
investment, disruptive
effects, quality controls
desirable prior to
unrestricted diffusion,
uncertainty regarding
safety, low quality of
evidence,
generalisability
Reducing uncertainty
regarding impact,
short or long term
health outcomes, risk
of inappropriate
decision and use
Reducing uncertainty
about beneﬁt of
promising new
methods,
commercial interest
of applicant
New and existing forms of
health care; data must be
collected on effectiveness
and/or cost-effectiveness
Use of new or
promising
technology/public
health intervention;
uncertainty about
efﬁcacy, safety and
cost-effectiveness
Relevance to health
outcomes,
representativeness of
available evidence,
re-evaluation of
evidence base,
generalisability
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Table 2 (Continued)
Attributes Australia Canada (Ontario) France Germany The Netherlands UK (England/Wales) USA
Types of research
evidence/study
design required
Varies; preference
for high quality
clinical trials;
where suitable
well-designed
cohort,
case-control,
comparative and
diagnostic studies
Varies according to the
nature of the residual
uncertainty; (e.g.
clinical trials, registry
data, prospective
observational studies)
Studies have to meet
uncertainties raised
by the assessment;
type depends on the
lack of evidence and
level of uncertainty;
studies with the
highest LoE preferred
RCTs preferred (other
designs possible in
case of e.g. ethical
reasons)
Effectiveness requirement is
statutorily anchored (e.g.
data should be collected on
the highest possible LoE).
Varies: any form of
study type (e.g.
clinical trials,
registries,
observational studies
etc.) that will meet
ethical and research
governance
requirements
RCTs, registries, and
prospective cohort
studies. The type of
study depends on the
quality of the
existing evidence
Representative
examples
PET,  TUNA of the
prostate,
brachytherapy for
the treatment of
prostate cancer, . . .
PET, endovascular
abdominal aortic
aneurysm repair, drug
eluting stents, . . .
Extracranial
stereotactic
radiotherapy,
biochemical markers
of liver ﬁbrosis,
intensity-modulated
radiation therapy, . . .
Under consideration:
PET in three
oncologic indications
(incl. recurring colon
cancer, esophageal
cancer, melanoma),
. . .
Vaccination with autologous,
naturally circulating
dendritic cells loaded with
synthetic peptides in
malignant melanoma
patients (st IIIb/IIIC,
Rituximab maintenance
treatment for FL patients
responding to ﬁrst-line
induction therapy, . . .
MIST wound therapy
system,
electromechanical
gait training for
people after stroke,
screening for skin
cancer, . . .
Allo HSCT for the
treatment of
myelodysplastic
syndromes (MDS;
artiﬁcial heart
devices; cochlear
implants, . . .
Sources: Authors’ own  compilation based on available information in the public domain (websites), the literature given in the reference list of this article and e-mail exchange with experts from the regulatory
institutions and/or organisations involved.
a Refers to the policy called: Voorwaardelijke toelating.
b The Canada Health Act establishes the criteria/conditions related to insured health services and extended health care services that provinces/territories must fulﬁl to qualify for their full share of the federal
cash  contributions under the Canada Health Transfer.
c Laboratory tests of devices and retrospective surveys of existing data can be fully-funded by NICE. NICE do not fund clinical trials of devices on patients once recruitment starts, but NICE do facilitate the
production of protocols, ethical opinion, peer-review and administration related to research governance. NICE can also recommend that big studies, such as large multicenter RCTs, are funded by UK public
funders  such as the NIHR and MRC. There is no guarantee that NICE’s recommendations for research will be implemented by these funding bodies. Allo HSCT = allogeneic hematopoietic stem cell transplan-
tation;  AHRQ = Agency for Healthcare Research and Quality (AHRQ); ASCT = autologous stem cell transplantation; CED = coverage with evidence development; Zorginstituut Nederland = health care insurance
board;  DBC-O = diagnose behandeling combinatie-onderhoud; DG = diagnostics guidance; FL = follicular lymphoma; GP = general practitioner; HBOT = hyperbaric oxygen treatment; IPG = interventional proce-
dures  guidance; IQWiG = Institute for Quality and Efﬁciency in Healthcare; LoE = level of evidence; MAS = medical advisory secretariat (Ontario); MOHLTC = Ministry of Health and Long-Term Care; MRC  = Medical
Research  Council; MSAC = Medical Services Advisory Committee; MTG  = medical technologies guidance; NIHR = National Institute for Health Research; NHS = National Health Service; NHS R&D = NHS Research
and  Development Forum; NICE = National Institute for Health and Care Excellence; NZa = Nederlandse Zorgautoriteit; OHTAC = Ontario Health Technology Advisory Committee; PATH = Program for the Assess-
ment  of Technologies in Health (Ontario); PET = positron emission tomography; st = stadium; THETA = Toronto Health Economics and Technology Assessment Collaborative; TUNA = transurethral needle ablation;
VerfO  = Verfahrensordnung (rules of procedure); ZonMW = Netherlands organisation for Health Research and Development.
d Excludes drugs on the Ontario Drug Beneﬁt Program or Information Systems/Information Technology related technologies.
e Until 2012 mainly expensive inpatient drugs, from January 2013 so called ‘specialist drugs’. Conditional entry is not possible for other care forms (e.g. medical devices or oral health care).
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rocesses and methods. As explained in the introduction,
ED schemes have the main objective to generate evidence
or the ﬁnalisation of a coverage decision and to inform
uture decisions [3,13,32,33]. However, uncertainty about
he cost-effectiveness is an additional motivating factor
onsidered speciﬁcally in countries like Australia, the UK
nd The Netherlands, but playing a minor part in other
ountries including Germany. Nevertheless, all schemes
ave a strong legal foundation and are anchored in existing
egislation, such as the German SGB V. Evidence develop-
ent in most systems is, at least in parts, funded publicly.
owever, the share of manufacturers in the funding of
tudies to a higher degree than in Germany is observable.
ontrary to Germany, most countries rely on their Min-
stry of Health (MoH) (or their equivalent governmental
ody) as a decision maker in their CED implementation.
nly the UK takes an approach similar to that of Germany,
y mandating an operationally independent public body –
he National Institute for Health and Care Excellence (NICE)
 to oversee the British CED scheme [34]. All countries have
n common that they rely on additional third parties in any
perational steps (e.g. study planning and execution) of
heir CED schemes.
Turning from the political aspects of CED schemes
o their speciﬁc scope, we make the following observa-
ions. All countries except for The Netherlands, which
ainly consider orphans and expensive inpatient pharma-
eutical products, focus on non-drug methods including
rocedures (surgical and non-surgical), diagnostic tests
nd medical services [35,36]. In addition the UK differs
rom the remainder of countries because it also considers
ublic health interventions. Furthermore, while Germany
olely addresses new diagnostic and therapeutic methods,
ost countries focus on both existing and new treatment
ptions. The German system is also the only one consider-
ng coverage applications for methods not relying mainly
n a medical device. No country restricts its CED scheme
o a speciﬁc indication or condition. Applications range
rom prevalent to rare and from life threatening to non-life
hreatening diseases. Finally, we consider the types of study
esign applicable in the selected systems. Data is gath-
red either experimentally and prospectively (e.g. RCTs) or
nder real-life conditions (e.g. registries). While the rules
f procedure in Germany mandate RCTs, except if they are
ot applicable for ethical or other reasons, other countries
nly state strong preference for evidence from high qual-
ty RCTs [7,8,26]. Therefore, there are no clear restrictions
egarding the study designs to be used during CED in these
ases.
From the above comparison we gather that the selected
ED schemes depend on the speciﬁc context in which
overage decisions are made in individual healthcare sys-
ems. This dependence manifests itself in various details of
heir implementations. Similar ﬁndings have been revealed
n previous research [7,13,33]. However, the compari-
on also exposes the existence of common characteristics
mong CED schemes, most importantly a clear legisla-
ive foundation, a deﬁnitive and possibly independent
ecision-making body, the possibility to obtain public
unding for the evaluation, and the preference for high
uality study designs. Therefore, despite the differences in 117 (2014) 135–145 143
the systems’ speciﬁcs, these characteristics can be made
out as the basis for a developing international standard
in CED.
In any case, for a successful CED implementation, one
needs to identify the circumstances or technologies suit-
able for the application of CED in a clear and transparent
way, which involves all relevant stakeholders includ-
ing healthcare providers, decision makers, manufacturers,
and patients [3,13]. Experts in- and outside Europe have
been focusing on this speciﬁc issue in recent years. A
relevant example in this context are the results of the
2008 HTAi meeting, summarised by Trueman et al. [6,37].
The summary provides a helpful set of criteria facilitat-
ing the identiﬁcation of technologies suitable for CED
ex ante. These criteria concern (1) the research problem
(e.g. high unmet clinical need or signiﬁcant improvement
in outcomes), (2) the value proposition of a technol-
ogy (e.g. is the proposition logically and theoretically
valid), (3) appropriate data collection (e.g. study design),
(4) coverage tool selection (e.g. no coverage tool other
than CED is appropriate), (5) primary motivation for the
application of CED (e.g. reduction of uncertainty regarding
clinical and/or cost-effectiveness, no purely budgetary
reasons), (6) time-horizon of the evidence development
process (e.g. completion in a timely manner).
The new German regulation on CED meets most of these
criteria: Only methods with a clinical need will be con-
sidered (criterion 1), methods have to show a potential
for medical beneﬁt (2), applicants approach the G-BA in
order to generate necessary data that will ultimately lead
to a coverage decision (3) because there is not yet suf-
ﬁcient evidence on patient-related beneﬁt (5). Since the
German approach to CED is not an alternative to other
means of coverage (e.g. risk-sharing agreement), crite-
rion 4 does not apply. The G-BA seeks applications for
CED in an early phase of the method life-cycle (6); how-
ever, due to process requirements, time could become a
critical factor within a CED case. Although these criteria
appear to be useful, they still lack empirical validation
and should therefore be regarded as a proposal, not as a
standard.
5. Conclusion
Experiences with European and international health-
care systems show that controversial decisions for new
interventions made under uncertainty may  harm patients,
may  be ineffective, or might cause high economic bur-
dens. Introducing CED policy is a useful step to mitigate
these risks by offering preliminary access to promising
new technologies while generating the evidence needed
to decide whether full coverage of these technologies is
warranted. The introduction of the new CED scheme in
Germany, through section 137e SGB V, has enabled the
G-BA to demand and trigger evidence generation for new
diagnostic and therapeutic methods, whilst at least tem-
porarily including these methods in the SHI beneﬁt basket.
This change represents a powerful and necessary extension
of the previously existing exclusively prohibitive instru-
ments.
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Our comparison of this new German legislation with a
set of selected international CED schemes demonstrates
the dependence of CED implementations on the speciﬁcs
of the encompassing healthcare system. Nevertheless, we
are able to successfully identify a common base of key char-
acteristics in CED such as a clear legislative foundation, a
deﬁnitive decision-making body, the possibility to obtain
public funding, and the preference for high quality study
designs, which can be seen as forming an emerging inter-
national standard.
Due to the inherent logic of the CED approach, modern
healthcare systems should provide this option. The imple-
mentation is challenging because of its impact on relevant
stakeholders. Therefore it is of particular importance to
verify that the use of CED is appropriate under the given
circumstances or for speciﬁc technologies. The literature
has identiﬁed six important criteria for this veriﬁcation.
However, despite their usefulness these criteria still need
validation and should be further developed. We  addition-
ally recommend the introduction of systematic and regular
reporting into CEDs. This could be realised for example via
reporting systems or registries comparable to registries for
clinical trials.
The recent changes in Germany offer an opportunity
to observe a new CED scheme in action. The thereby
discovered information regarding the beneﬁts and pitfalls
of CED policy should ﬁnd consideration in a continued
debate on this issue.
Conﬂict of interest statement
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